Sequenom, Inc. (NASDAQ:SQNM), a leading provider of molecular diagnostic applications and genetic analysis products and services, today reported financial results for the three and nine months ended September 30, 2008.

Sequenom (NASDAQ:SQNM) today announced that it entered into an agreement to acquire the Center for Molecular Medicine (CMM), a Clinical Laboratory Improvement Act (CLIA) certified clinical diagnostics laboratory based in Grand Rapids, Michigan.

The Center for Molecular Medicine or CMM has announced the formation of a collaborative effort with its affiliates and Qiagen to support research focused on discovering molecular biomarkers capable of helping diagnose breast cancer and other women's health issues.

GRAND RAPIDS, Mich., Jan. 8 /PRNewswire/ -- The C

GRAND RAPIDS, Mich., June 13 /PRNewswire/ -- The Center for Molecular Medicine (CMM) today announced it is the first Midwest-based laboratory to offer the FDA-approved AmpliChip(R) CYP450 Test to physicians and hospitals.